Mutation analysis of a cohort of US patients with hemophilia B

American Journal of Hematology

Volumn 89, Issue 4, 2014, Pages 375-379

  Li, Tengguo ^a   Miller, Connie H ^a   Driggers, Jennifer ^a   Payne, Amanda B ^a   Ellingsen, Dorothy ^a   Hooper, W Craig ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FOUNDER EFFECT; FRAMESHIFT MUTATION; GENE DELETION; GENE INSERTION; GENE MUTATION; HAPLOTYPE; HEMOPHILIA B; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATION RATE; MUTATIONAL ANALYSIS; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; RECURRENT DISEASE; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CODON, NONSENSE; CONTINENTAL POPULATION GROUPS; EXONS; FACTOR IX; FOUNDER EFFECT; GENE FREQUENCY; HAPLOTYPES; HEMOPHILIA B; HUMANS; INFANT; INTRONS; ISOANTIBODIES; MALE; MUTAGENESIS, INSERTIONAL; MUTATION; POINT MUTATION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84897469007     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23645     Document Type: Article

References (28)

1. White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85:560.
2. Chance PF, Dyer KA, Kurachi K, et al. Regional localization of the human factor IX gene by molecular hybridization. Human Genet 1983;65:207-208.
3. Roberts HR. Molecular biology of hemophilia B. Thrombosis and haemostasis 1993;70:1-9.
4. Castaldo G, Nardiello P, Bellitti F, et al. Haemophilia B: from molecular diagnosis to gene therapy. Clinical chemistry and laboratory medicine: CCLM/FESCC 2003;41:445-451.
5. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: Results of a large-scale North American survey. Haemophilia 1996;2:28-31.
6. Radic CP, Rossetti LC, Abelleyro MM, et al. Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B. Thromb Haemost 2013;109:24-33.
7. Thorland EC, Drost JB, Lusher JM, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999;5:101-105.
8. Chitlur M, Warrier I, Rajpurkar M, et al. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009;15:1027-1031.
9. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003;361:1801-1809.
10. Rallapalli PM, Kemball-Cook G, Tuddenham EG, et al. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost 2013;11:1329-1340.
11. Li T, Miller CH, Payne AB, et al. The CDC Hemophilia B mutation project mutation list: a new online resource. Mol Genet Genomic Med 2013;doi:10.1002/mgg3.30.
12. Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol 2002;55:1-18.
13. Koeberl DD, Bottema CD, Buerstedde JM, et al. Functionally important regions of the factor IX gene have a low rate of polymorphism and a high rate of mutation in the dinucleotide CpG. Am J Human Genet 1989;45:448-457.
14. Thompson AR, Bajaj SP, Chen SH, et al. "Founder" effect in different families with haemophilia B mutation. Lancet 1990;335:418.
15. Sommer SS, Ketterling RP. The factor IX gene as a model for analysis of human germline mutations: an update. Human Mol Genet 1996;5 Spec No:1505-1514.
16. Belvini D, Salviato R, Radossi P, et al. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 2005;90:635-642.
17. Bicocchi MP, Pasino M, Rosano C, et al. Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B. Haemophilia 2006;12:263-270.
18. Jenkins PV, Egan H, Keenan C, et al. Mutation analysis of haemophilia B in the Irish population: increased prevalence caused by founder effect. Haemophilia 2008;14:717-722.
19. Yu T, Dai J, Liu H, et al. Spectrum of F9 mutations in Chinese haemophilia B patients: identification of 20 novel mutations. Pathology 2012;44:342-347.
20. Baker JR, Riske B, Drake JH, et al. US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization. Haemophilia 2013;19:21-26.
21. Miller CH, Benson J, Ellingsen D, et al. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia 2012;18:375-382.
22. Soucie JM, McAlister S, McClellan A, et al. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med 2010;38:S475-S481.
23. Yoshitake S, Schach BG, Foster DC, et al. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985;24:3736-3750.
24. Reitsma PH, Bertina RM, Ploos van Amstel JK, et al. The putative factor IX gene promoter in hemophilia B Leyden. Blood 1988;72:1074-1076.
25. Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 2011;12:683-691.
26. Ketterling RP, Bottema CD, Phillips JA 3rd, et al. Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States. Genomics 1991;10:1093-1096.
27. Giannelli F, Green PM, Sommer SS, et al. Haemophilia B: database of point mutations-and short additions and deletions-eighth edition. Nucleic Acids Res 1998;26:265-268.
28. Green PM, Montandon AJ, Bentley DR, et al. The incidence and distribution of CpG-TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots. Nucleic Acids Res 1990;18:3227-3231.